We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $1.61 | — | — | $11.72B | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $1.2 | — | — | $11.2B | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-4.45 | — | — | $35.96B |
Consensus PT $62.96 · 25 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 10. | B of A Securities | — | 의견 유지 | Buy → Buy | — | B of A Securities: Buy |
| 2026. 04. 08. | Guggenheim | — | 의견 유지 | Buy → Buy | — | Guggenheim: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-5.05 | — | — | $24.07B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 11,535,106 | $699.6B | 0.60% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 4,662,042 | $251.47B | 0.39% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Stored first · Google News · Yahoo Finance (English)
BioNTech and Bristol Myers Squibb Announce Promising Interim Data for Pumitamig Combined with Chemotherapy in First-Line Non-Small Cell Lung Cancer at ASCO 2026 - Quiver Quantitative
BioNTech and Bristol Myers Squibb Announce Promising Interim Data for Pumitamig Combined with Chemotherapy in First-Line Non-Small Cell Lung Cancer at ASCO 2026 Quiver Quantitative
Norges Bank Acquires Shares of 36,100,698 Bristol Myers Squibb Company $BMY - MarketBeat
Norges Bank Acquires Shares of 36,100,698 Bristol Myers Squibb Company $BMY MarketBeat
Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY MarketBeat
Fideuram Asset Management Ireland dac Takes Position in Bristol Myers Squibb Company $BMY - MarketBeat
Fideuram Asset Management Ireland dac Takes Position in Bristol Myers Squibb Company $BMY MarketBeat